MedTrace Logo

tDCS as an Adjuvant to Intensive Speech Therapy for Chronic Post Stroke Aphasia

NCT02801864 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2017-07-02

No results posted yet for this study

Summary

The purpose of this study is to determine if transcranial direct current stimulation (tDCS) in conjunction with intensive speech therapy will improve sentence production and word retrieval in individuals with chronic post stroke aphasia.

Conditions

  • Aphasia
  • Language

Interventions

DEVICE

Real tDCS

Participants will receive tDCS at 1mA for 20min of the total three hours of intensive speech therapy time at the beginning of each session. Stimulation will be provided via an electrode using a Starstim device.

DEVICE

Sham tDCS

Participants will receive tDCS at 1mA for 20min of the total three hours of intensive speech therapy time at the beginning of each session. Stimulation will be provided via an electrode using a Starstim device.

OTHER

Intensive Speech Therapy

Participants will receive one hour of group therapy and two hours of individual therapy that will follow VNeST format. The purpose of therapy will be to have the client generate verbs and nouns in written and verbal form.

Sponsors & Collaborators

  • Burke Medical Research Institute

    collaborator OTHER

  • University of Texas

    collaborator OTHER

  • Austin Speech Labs

    lead OTHER

Principal Investigators

  • Thomas Marquardt, Ph.D. · University of Texas at Austin

  • Shilpa Shamapant, M.S.,M.A. · Austin Speech Labs

  • Dylan Edwards, Ph.D. · Burke Medical Rehabilitation and Research Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2018-12-31
Completion
2019-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02801864 on ClinicalTrials.gov